Curated News
By: NewsRamp Editorial Staff
September 21, 2026
GeoVax's Single-Dose MVA-X Vaccine Shows Durable Protection Against Mpox
TLDR
- GeoVax's single-dose MVA-X vaccine matches two-dose protection, offering a strategic edge in outbreak response and biodefense markets.
- MVA-X uses an immunomodulatory peptide to boost CD8+ T-cell responses, providing durable single-dose protection against Clade I mpox in preclinical models.
- GeoVax's single-dose mpox vaccine could simplify outbreak response and protect at-risk populations, especially in resource-limited settings.
- GeoVax's MVA-X vaccine protected mice against lethal mpox for 150 days after just one dose, even as antibody levels declined.
Impact - Why it Matters
This news matters because it could revolutionize mpox outbreak response. A single-dose vaccine would drastically simplify vaccination campaigns, especially in resource-limited settings where cold-chain and follow-up logistics are challenging. With mpox outbreaks becoming more frequent and Clade I associated with severe disease, a durable one-shot option could accelerate protection for at-risk populations and strengthen global biosecurity. Moreover, the findings highlight the critical role of CD8+ T cells in long-term immunity, potentially informing next-generation vaccine design beyond mpox.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers, has announced promising preclinical results for its next-generation MVA vaccine candidate, MVA-X. Published on bioRxiv, the study titled “Single-dose Efficacy of a Next-Generation Mpox Vaccine Harnessing an Immunomodulatory Peptide” demonstrates that a single dose of MVA-X provided durable protection against lethal orthopoxvirus challenges, including highly pathogenic Clade I mpox virus, in a susceptible animal model. The research, conducted with Washington State University and funded by GeoVax, showed that MVA-X elicited complete protection at days 55, 90, and 150 post-vaccination—comparable to a conventional two-dose MVA regimen—while also restricting viral replication and generating durable antigen-specific CD8+ T-cell responses. The manuscript is available as a bioRxiv preprint here.
David Dodd, Chairman and CEO of GeoVax, highlighted the potential impact: “During an outbreak, reducing a two-dose regimen to a single vaccination could simplify deployment, accelerate completion of vaccination programs and reduce the logistical burden associated with protecting at-risk populations.” The findings support GeoVax’s broader strategy to expand the utility of the MVA platform, including continuous cell-line manufacturing and needle-free microarray patch delivery. The company’s lead program, GEO-MVA, is advancing under an expedited regulatory pathway with a pivotal Phase 3 trial planned for the second half of 2026. For more information, visit www.geovax.com.
Mark Newman, Ph.D., Chief Scientific Officer, noted that the data underscore the important role of CD8+ T cells in controlling orthopoxvirus infection and support further investigation of MVA-X as a single-dose vaccine approach. The research was originally released via NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, GeoVax's Single-Dose MVA-X Vaccine Shows Durable Protection Against Mpox
